Skip to main content

Advertisement

Log in

In vitro acute and developmental neurotoxicity screening: an overview of cellular platforms and high-throughput technical possibilities

  • Review Article
  • Published:
Archives of Toxicology Aims and scope Submit manuscript

Abstract

Neurotoxicity and developmental neurotoxicity are important issues of chemical hazard assessment. Since the interpretation of animal data and their extrapolation to man is challenging, and the amount of substances with information gaps exceeds present animal testing capacities, there is a big demand for in vitro tests to provide initial information and to prioritize for further evaluation. During the last decade, many in vitro tests emerged. These are based on animal cells, human tumour cell lines, primary cells, immortalized cell lines, embryonic stem cells, or induced pluripotent stem cells. They differ in their read-outs and range from simple viability assays to complex functional endpoints such as neural crest cell migration. Monitoring of toxicological effects on differentiation often requires multiomics approaches, while the acute disturbance of neuronal functions may be analysed by assessing electrophysiological features. Extrapolation from in vitro data to humans requires a deep understanding of the test system biology, of the endpoints used, and of the applicability domains of the tests. Moreover, it is important that these be combined in the right way to assess toxicity. Therefore, knowledge on the advantages and disadvantages of all cellular platforms, endpoints, and analytical methods is essential when establishing in vitro test systems for different aspects of neurotoxicity. The elements of a test, and their evaluation, are discussed here in the context of comprehensive prediction of potential hazardous effects of a compound. We summarize the main cellular characteristics underlying neurotoxicity, present an overview of cellular platforms and read-out combinations assessing distinct parts of acute and developmental neurotoxicology, and highlight especially the use of stem cell-based test systems to close gaps in the available battery of tests.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Abbreviations

AD:

Alzheimer’s disease

ALS:

Amyotrophic lateral sclerosis

APC:

Automated patch-clamp

ASD:

Autism spectrum disorders

BBB:

Blood–brain barrier

CMP:

Cell membrane potential

CNS:

Central nervous system

DA:

Dopaminergic

DNT:

Developmental neurotoxicity

ECs:

Endothelial cells

ENT:

Engineered neural tissue

ER:

Endoplasmic reticulum

EST:

Embryonic stem cell test

FI:

Fluorescence intensity

FTD:

Frontotemporal dementia

hESCs:

Human embryonic stem cells

hiPSCs:

Human-induced pluripotent stem cells

HT:

High throughput

IATA:

Integrated approaches to testing and assessment

ITS:

Integrated testing strategies

KE:

Key event

MEA:

Multielectrode array or microelectrode array

NPC:

Neural progenitor cell

NT:

Neurotoxicity

OECD:

Organisation for Economic Co-operation and Development

PD:

Parkinson’s disease

PNS:

Peripheral nervous system

SOD1:

Cu/Zn-binding superoxide dismutase

TALEN:

Transcription activator-like effector nucleases

References

Download references

Acknowledgments

This work was supported by EU FP7 and H2020 projects (EpiHealth, HEALTH-2012-F2-278418; EpiHealthNet, PITN-GA-2012-317146, STEMCAM, PIAP-GA-2009-251186; STEMMAD, PIAPP-GA-2012-324451, EU-ToxRisk H2020-PHC-2015-681002), the Research Centre of Excellence 11476-3/2016/FEKUT, the NIH transformative research project on ‘Mapping the Human Toxome by Systems Toxicology’ (R01ES020750), the DFG (KoRS-CB, RTG1331) and the BMBF (Neuritox).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to András Dinnyés.

Ethics declarations

Conflict of interest

B.Z.S, M. Lehman, E.N., H.X.A., J.K., and A.D. had been or are involved in a company that produces iPSCs, does neural differentiation, and has a commercial interest in the field of (developmental) neurotoxicity testing and stem cell products. S.N. is married to B.Z.S. T.H. is cofounder of Organome LLC, the licensee of a provisional patent filed by Johns Hopkins University for a human mini-brain mentioned in this paper (inventors David Pamies, Helena Hogberg and Thomas Hartung). L.S. is married to T.H.

Additional information

Béla Z. Schmidt, Martin Lehmann, and Simon Gutbier have contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Schmidt, B.Z., Lehmann, M., Gutbier, S. et al. In vitro acute and developmental neurotoxicity screening: an overview of cellular platforms and high-throughput technical possibilities. Arch Toxicol 91, 1–33 (2017). https://doi.org/10.1007/s00204-016-1805-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00204-016-1805-9

Keywords

Navigation